Your browser doesn't support javascript.
loading
Strengthening regulatory science in academia: STARS, an EU initiative to bridge the translational gap.
Starokozhko, Viktoriia; Kallio, Marko; Kumlin Howell, Åsa; Mäkinen Salmi, Anna; Andrew-Nielsen, Gunilla; Goldammer, M; Burggraf, Manja; Löbker, Wiebke; Böhmer, Anne; Agricola, Eleonora; de Vries, Corinne S; Pasmooij, Anna M G; Mol, Peter G M.
  • Starokozhko V; Medicines Evaluation Board, Utrecht, The Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Kallio M; Finnish Medicines Agency, Helsinki, Finland.
  • Kumlin Howell Å; Swedish Medical Products Agency, Uppsala, Sweden.
  • Mäkinen Salmi A; Swedish Medical Products Agency, Uppsala, Sweden.
  • Andrew-Nielsen G; Swedish Medical Products Agency, Uppsala, Sweden.
  • Goldammer M; Division of Immunology, Paul Ehrlich Institute, Langen, Germany.
  • Burggraf M; Division Major Policy Issues, Coordination, Paul Ehrlich Institute, Langen, Germany.
  • Löbker W; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Böhmer A; Federal Institute for Drugs and Medical Devices, Bonn, Germany.
  • Agricola E; Italian Medicines Agency, Rome, Italy.
  • de Vries CS; European Medicines Agency, Amsterdam, The Netherlands.
  • Pasmooij AMG; Medicines Evaluation Board, Utrecht, The Netherlands.
  • Mol PGM; Medicines Evaluation Board, Utrecht, The Netherlands; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: p.mol@cbg-meb.nl.
Drug Discov Today ; 26(2): 283-288, 2021 02.
Article en En | MEDLINE | ID: mdl-33127567
ABSTRACT
Truly disruptive medicine innovation and new treatment paradigms tend to start in non-commercial research institutions. However, the lack of mutual understanding between medicine developers and regulators when it comes to medicine development significantly delays or even prevents the access of patients to these innovations. Here, we outline what regulatory-related barriers hamper the translational development of novel products or new treatment paradigms initiated in academia, and propose key steps towards improved regulatory dialogue among academia, funding bodies and regulatory authorities. Moreover, we briefly describe how the STARS (Strengthening Training of Academia in Regulatory Science) project aims to reach out to medicine innovators in academia to bridge the regulatory knowledge gap and enhance this dialogue to facilitate the implementation of academic research findings in clinical practice.
Asunto(s)

Texto completo: 1 Ejes tematicos: Inovacao_tecnologica Banco de datos: MEDLINE Asunto principal: Difusión de Innovaciones / Investigación Biomédica Traslacional Tipo de estudio: Prognostic_studies / Sysrev_observational_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Ejes tematicos: Inovacao_tecnologica Banco de datos: MEDLINE Asunto principal: Difusión de Innovaciones / Investigación Biomédica Traslacional Tipo de estudio: Prognostic_studies / Sysrev_observational_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article